Skip to content

    Insecticid.India

    INSECTICID
    Chemicals·28 May 2025
    Management Summary

    Insecticides India Limited reported a strong Q4 and FY25, driven by new product launches, premium product mix, and improved margins. The Dahej plant is set to commence production in June, expected to significantly contribute to FY26 revenue. While strategic inventory buildup and manpower shortages were noted, management expressed confidence in continued double-digit growth and margin improvement.

    Highlights

    5
    • Strong revenue growth of ~32% in Q4 FY25, driven by premium products like Shinwa, Izuki, Mission, Mycoraja, and new launches.

    • Gross profit margin for FY25 improved to 32%, a 655 bps increase over last year, due to better product mix and improved pricing strategy.

    • EBITDA margin for FY25 improved by 281 bps to 11.1%, and Q4 EBITDA improved by 226% to 7.9%.

    • Dahej plant, with an investment of Rs. 150 crores, received in-principle approval and will commence production in June 2025, expected to contribute ~Rs. 100 crores in FY26.

    • Successful launch of 12 products in FY25, with 4 elevated to Focused Maharatna, indicating strong market acceptance.

    Concerns

    2
    • Manpower shortages due to an unspecified 'war' situation impacted operations, potentially affecting Q1 FY26 placements.

    • Inventory buildup at March 31, 2025, though stated as strategic for the upcoming season, could be a concern if demand does not materialize as expected.

    What Changed2

    vs Q1 FY26

    Guidance items13 → 7 (-6)Risks discussed4 → 2 (-2)
    Key financials

    Metrics

    13

    Periods

    2

    Q4 FY25

    5
    • Revenue Growth
      32%
      YoY+32%
    • Gross Profit Margin
      51%
    • EBITDA Margin
      7.9%
    • PAT
      3.9%
    • Volume Growth
      40%
      YoY+40%

    FY25

    8
    • Revenue Growth
      2%
      YoY+2%
    • Gross Profit Margin
      32%
    • EBITDA Margin
      11.1%
    • PAT
      7%
    • ROCE
      18%

    Segment breakdown

    B2C Sales (FY25)
    61% Share of Overall B2C Sales
    B2C Sales (Q4 FY25)
    51% Share of Overall B2C Sales
    B2B Sales (FY25)
    20% Share of Overall Sales
    B2B Sales (Q4 FY25)
    27% Share of Overall Sales
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹100 crores

    M&A

    Kaeros

    acquisition · integrated · Consideration ₹NaN (undisclosed)

    Liquidity

    Liquidity disclosed

    Strategic inventory buildup at March 31, 2025, in anticipation of good monsoon predictions and new season demand, expected to be sold by June-July.

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    Dahej Plant Contribution
    ~Rs. 100 crores
    High
    Capacity
    Dahej Plant Expansion CAGR
    >50%
    High
    Profitability
    Kaeros Profit Contribution
    Rs. 10-12 crores
    High
    Profitability
    Net Profit Margin
    10%
    Medium
    Product Launches
    New Product Launches
    6 products
    High
    Margin
    EBITDA Margin Improvement
    200 to 300 bps
    Medium
    Headcount
    Salary Budget CAGR
    15%
    High

    Dahej Plant Production & Revenue

    next quarter
    CurrentIn-principle approval received, production to start June 2025
    TargetCommencement of production and initial revenue contribution of ~Rs. 100 crores in FY26

    Why it matters

    Successful commissioning and revenue generation from the Dahej plant are crucial for FY26 growth targets.

    And now this plant has received the in-principle approval from the government, which means that in the month of June, we will start our production. ... this year this plant is going to contribute roughly about Rs. 100 crores

    How to verify

    guidance_and_targets[category='Revenue'][metric='Dahej Plant Contribution']

    Risks & concerns

    2
    RiskSeverity

    Manpower shortages

    Manpower shortages due to an unspecified 'war' situation impacted operations, particularly in June, affecting production capacity.Management acknowledged

    medium

    Potential for China dumping due to US tariffs

    Analyst raised concern about US tariffs on China leading to dumping in India, but management stated it's less likely due to product registration requirements in India.Analyst downplayed

    low

    Q&A highlights

    8

    “So, in the full year, the volume growth has been roughly about 10%. The average price decline during the year is around 8%. So, the total growth in terms of numbers is showing about 2%. ... Quarter I have not checked myself, but quarter slides we are showing a decrease of 32%. So, you can increase that so roughly volume growth will be around 40% odd.”

    Clarified the underlying volume growth for the quarter and full year, which was masked by price declines in FY25.

    asked by Bharat Gupta

    2 min read7 chapters

    Detailed Narrative

    01

    Strong Industry Outlook and Monsoon Preparedness

    The company noted a very positive sentiment across the industry, driven by good monsoon predictions and pre-monsoon showers. Crop sowing is expected to start early, with farmers experiencing good earnings from rabi season crops. This favorable environment, coupled with stable raw material prices, sets a positive outlook for fiscal 2026.

    02

    Record New Product Launches and Maharatna Strategy

    Insecticides India launched a record 12 new products in FY25, with 4 of these successfully moving into the Focused Maharatna category, increasing the total to 16. These new products have received strong acceptance from farmers and trade, contributing to growth. The company plans to launch another 6 products in FY26, including 'Altair' from Nissan, a patented herbicide for rice.

    03

    Dahej Plant Commissioning and Capacity Expansion

    The Dahej plant, following an investment of Rs. 150 crores, has received in-principle approval and is set to commence production in June 2025. This plant is expected to contribute approximately Rs. 100 crores to revenue in FY26 and is projected to achieve a CAGR of over 50% in the next 3-4 years. Additionally, Rs. 50 crores has been spent on the Sotanala plant, with another Rs. 100 crores planned for FY26, primarily for Sotanala.

    04

    Robust Financial Performance in Q4 and FY25

    The company reported a strong Q4 FY25 with revenue growth of around 32% and volume growth of approximately 40%. For the full year FY25, gross profit margin improved by 655 bps to 32%, driven by a better product mix and improved pricing. EBITDA margin for FY25 increased by 281 bps to 11.1%, and PAT for FY25 stood at 7%. ROCE and ROE also improved to 18% and 13% respectively.

    05

    Strategic Inventory Management and Market Positioning

    An increase in inventory at March 31, 2025, was a strategic move in anticipation of good monsoon predictions and the upcoming season. This inventory is expected to be sold by June-July. The company aims for double-digit growth, focusing on premium products and effective inventory control, positioning itself to outperform the market.

    06

    Kaeros Acquisition Delivering Expected Returns

    The acquisition of Kaeros for approximately Rs. 5-6 crores has been positive, generating about Rs. 2 crores in profit in its first year. The company expects Kaeros to contribute Rs. 10-12 crores in profit in FY26, indicating a 100% recovery of the acquisition cost and significant future growth potential as it scales up.

    07

    Manpower Challenges and Operational Adjustments

    The company faced manpower shortages due to an unspecified 'war' situation, which impacted operations, particularly in June. While this posed a challenge to achieving 100% of desired output, management is working to mitigate the impact and expects recovery. Other expenses increased by Rs. 57 crores, primarily due to aggressive business promotion and field activities for new product launches.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.